Evoke Pharma (EVOK) Receives Coverage Optimism Score of 0.05
Headlines about Evoke Pharma (NASDAQ:EVOK) have trended somewhat positive on Friday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Evoke Pharma earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 45.7517881769829 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- Traders Alert on Evoke Pharma, Inc. (EVOK) – Wall Street Morning (wallstreetmorning.com)
- Workday, Inc. (WDAY) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS (vothemes.com)
- Evoke Pharma Inc (EVOK) Shares Climb Above Balance Step – Sparta Review (spartareview.com)
- Evoke Pharma, Inc. (EVOK) Lifted to “Hold” at ValuEngine (americanbankingnews.com)
Shares of Evoke Pharma (NASDAQ:EVOK) traded up 3.17% on Friday, reaching $2.60. 30,689 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $2.43 and a 200-day moving average price of $2.70. Evoke Pharma has a 12-month low of $1.35 and a 12-month high of $4.55. The company’s market cap is $40.01 million.
Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.15. During the same quarter in the previous year, the firm earned ($0.41) EPS. Equities research analysts anticipate that Evoke Pharma will post ($0.88) EPS for the current fiscal year.
A number of equities research analysts have recently weighed in on EVOK shares. FBR & Co reaffirmed a “buy” rating and set a $9.00 target price on shares of Evoke Pharma in a research note on Thursday, May 18th. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Evoke Pharma in a research report on Tuesday, August 15th. ValuEngine raised shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th. Finally, Zacks Investment Research cut shares of Evoke Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $7.25.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Stock Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related stocks with our FREE daily email newsletter.